Form 25 Sunoco LP
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D. C. 20549
FORM 25
NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.
| Commission File Number | 001-35653 | |||||||
| SUNOCO LP New York Stock Exchange | ||||||||
| (Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered) | ||||||||
| 8111 Westchester Drive, Suite 400, Dallas, Texas 75225 (214) 981-0700 | ||||||||
| (Address, including zip code, and telephone number, including area code, of Issuer’s principal executive offices) | ||||||||
| Common Units Representing Limited Partner Interests | ||||||||
| (Description of class of securities) | ||||||||
Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:
☐ | 17 CFR 240.12d2-2(a)(1) | ||||
☐ | 17 CFR 240.12d2-2(a)(2) | ||||
☐ | 17 CFR 240.12d2-2(a)(3) | ||||
☐ | 17 CFR 240.12d2-2(a)(4) | ||||
☐ | Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange.1 | ||||
Q | Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with the rules of the Exchange and the requirements of 17 CFR 240.12d2-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange. | ||||
Pursuant to the requirements of the Securities Exchange Act of 1934, Sunoco LP certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.
| SUNOCO LP | |||||||||||
| By: | Sunoco GP LLC, its general partner | ||||||||||
| Date: | September 28, 2026 | /s/ Dylan A. Bramhall | |||||||||
| Dylan A. Bramhall | |||||||||||
| Executive Vice President and Group Chief Financial Officer | |||||||||||
1 Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Sunoco LP and SunocoCorp LLC Announce Third Quarter 2026 Earnings Release and Call Timing
- Summit Therapeutics Announces Clinical Trial Collaboration with AstraZeneca and Daiichi Sankyo to Evaluate Ivonescimab in Combination with TROP2-Directed ADC Datroway
- Inspo Dental Honors Veterans and First Responders With Free Dental Services on Veterans Day
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share